Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...
CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...
For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...
Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption ...
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin ...
Insulet's Omnipod 5 device is the first such system to be cleared for use in managing both type 1 and type 2 diabetes. The medical device maker has been working to ease investor concerns about the ...
Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. Get real-time ...
On Thursday, Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. The automated insulin delivery ...